Can a common heart drug improve how the heart relaxes?
NCT ID NCT07157527
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether the drug sacubitril/valsartan (Entresto) can improve the heart's ability to relax in people with heart failure and reduced pumping strength. Researchers will use ultrasound to measure changes after six months of treatment. The study involves 70 adults from two heart centers in Egypt.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacubitril/valsartan (Entresto)
- What this could lead to
- If successful, this could show that sacubitril/valsartan improves heart relaxation in patients with heart failure and reduced pumping ability, potentially guiding better treatment.
- What could go wrong
- This is a small, early-stage observational study with only 70 participants. It may not prove long-term benefits, and results may not apply to all heart failure patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could continuing a common heart drug before surgery save lives?
- Could a natural chemical be the key to safer heart failure treatment?
- Can a Breathing-Synchronized pacemaker boost heart function after bypass?
- Can 3D heart scans outperform standard ultrasound in predicting risk?
- Iron infusions put to the test for heart failure stamina
- Zapping lung nerves could ease heart Failure-Related high blood pressure